Rene Russo - May 1, 2024 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Chris Frankenfield, Attorney-in-Fact
Stock symbol
XLO
Transactions as of
May 1, 2024
Transactions value $
$0
Form type
4
Date filed
5/3/2024, 04:10 PM
Previous filing
Jan 3, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Stock Option (right to buy) Award $0 +474K $0.00 474K May 1, 2024 Common Stock 474K $1.08 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option award was granted on May 1, 2024 and shall vest on June 1, 2024 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until May 1, 2028.